Macrolide treatment for COVID-19: Will this be the way forward?
| Autor: | Houman Goudarzi, S Jodo, Yoshihiro Kusunoki, Masahide Seki, Ken Furuya, Haruki Shida, Masashi Ohe |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Drug
medicine.medical_specialty Health (social science) Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) media_common.quotation_subject Pneumonia Viral Azithromycin Antiviral Agents General Biochemistry Genetics and Molecular Biology Betacoronavirus Structure-Activity Relationship 03 medical and health sciences Human health 0302 clinical medicine Pandemic medicine Humans Protease Inhibitors Intensive care medicine Pandemics media_common SARS-CoV-2 business.industry COVID-19 macrolide Hydroxychloroquine General Medicine COVID-19 Drug Treatment Clinical trial 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Macrolides Coronavirus Infections business medicine.drug |
| Zdroj: | BioScience Trends. 14:159-160 |
| ISSN: | 1881-7823 1881-7815 |
| DOI: | 10.5582/bst.2020.03058 |
| Popis: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic that has developed in late 2019 and 2020 is a serious threat to human health. With no vaccines or drugs approved for prevention and treatment until now, all efforts at drug design and/or clinical trials of already approved drugs are worthy and creditable. Using structure-based drug selection for identification of SARS-CoV-2 protease inhibitors, old drugs such as macrolides (MAC) were predicted to be effective for COVID-19. Lately, the anti-viral effects of macrolides have attracted considerable attention. Very recently, hydroxychloroquine in combination with azithromycin treatment was reported to be effective for COVID-19. We believe that treatments with macrolides alone or in combination with other drugs are promising and open the possibility of an international strategy to fight this emerging viral infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|